The United Kingdom and the United States have signed a landmark bilateral deal that will guarantee no tariffs on British pharmaceutical shipments entering the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to raise spending on medicines through the National Health Service (NHS). This pledge ensures that import taxes on these crucial goods will remain at zero for a timeframe of 36 months.
This development comes after recent statements to hike duties on branded drug products, with potential rates mentioned as high as double the cost.
"This agreement with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed balance to American-British drug exports," an announcement declared.
Trade Impact
Medicines constitute one of the the United Kingdom's biggest exports to the US, which is clearly the biggest destination for leading British pharmaceutical firms.
Statistics indicate that in the year prior to September, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This amount represented a significant portion of total UK exports in that span.
"This deal secures work, boosts capital expenditure and sets the stage for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific NHS Changes
The pact involves several specific changes from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to raise overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. In the past, refunds exceeded twenty percent.
Recent Tensions
The pact comes amid a protracted tension between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were exacerbated by claims that US consumers were charged a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had declined as a share of its total funding over the previous ten-year period.
